Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have received a consensus rating of "Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $21.00.

A number of research firms recently weighed in on REPL. Cantor Fitzgerald started coverage on Replimune Group in a report on Friday, June 20th. They set an "overweight" rating for the company. Piper Sandler upped their price target on shares of Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a research report on Monday, June 2nd. HC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of Replimune Group in a report on Thursday, July 3rd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock an "overweight" rating in a research note on Wednesday.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 7,952 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $64,093.12. Following the transaction, the insider directly owned 146,933 shares of the company's stock, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Christopher Sarchi sold 3,749 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the completion of the transaction, the insider directly owned 128,296 shares in the company, valued at $1,032,782.80. This trade represents a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,907 shares of company stock worth $603,655 in the last ninety days. Corporate insiders own 8.80% of the company's stock.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in REPL. Price T Rowe Associates Inc. MD boosted its position in Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after purchasing an additional 1,083,633 shares in the last quarter. Redmile Group LLC boosted its holdings in shares of Replimune Group by 2.6% in the 4th quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after buying an additional 124,344 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Replimune Group by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock worth $37,372,000 after buying an additional 237,185 shares during the last quarter. Tang Capital Management LLC grew its position in shares of Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after buying an additional 1,500,000 shares during the last quarter. Finally, RTW Investments LP raised its stake in shares of Replimune Group by 82.1% during the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock worth $25,007,000 after acquiring an additional 931,223 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Stock Performance

Shares of NASDAQ REPL opened at $12.09 on Friday. Replimune Group has a one year low of $6.44 and a one year high of $17.00. The business's 50-day moving average price is $9.53 and its two-hundred day moving average price is $10.48. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.95 and a quick ratio of 7.95. The company has a market capitalization of $932.02 million, a P/E ratio of -3.94 and a beta of 0.61.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the company earned ($0.25) earnings per share. Analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.